Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Telecom Stocks Bleed
Fri, 8 Jul Closing

Major Asian markets finished today's session on a negative note as of the most recent closing prices. Stock markets in Japan and China ended the day lower by 1.1% and 0.9% respectively. At the time of writing, most of the European markets are trading in the green.

Back home, Indian equity markets ended the day on a negative note. Sectoral indices ended the day in red with stocks from telecom and oil & gas sector witnessing maximum selling pressure.

The BSE-Sensex ended the day lower by 74 points, while the NSE-Nifty too ended lower by about 15 points. However, BSE Mid Cap ended the day marginally higher by 0.1%. While, BSE Small Cap closed lower by 0.2%. The rupee was trading at 67.45 against the dollar at the time of writing.

As per an article in Livemint, Cipla is planning to invest in a biotech plant in South Africa. The company is eyeing a manufacturing facility of biosimilars at a projected cost of Rs 6 billion.

The project is aimed at making the cancer drugs affordable and growing its presence in the market. The plant will be set up at a special economic zone in Durban and is expected to commence production by 2018.

The company already has a presence in the South African market. Currently, South African market contributed around 14% to the company's consolidated sales in the financial year FY15.

Biosimilars is an emerging megatrend opportunity in the pharma space and a lot of value could potentially be unlocked in this area. Recently, we had written an article pertaining to Indian companies trying to capitalize on the biosimilar opportunity. Click here (subscription required) to read this interesting piece. The stock of Cipla ended the day trading higher by 1.3%.

In another news update, five private equity firms are in the race to buy a 10% stake in Hero FinCorp. Hero FinCorp is a subsidiary of Hero MotoCorp Ltd. Hero FinCorp is in the business of vehicle finance.

Hero MotoCorp is looking to dilute 10% stake in Hero FinCorp. Reportedly, Hero MotoCorp is expected to raise US$ 120 million from this stake sale. This means that the deal would value Hero FinCorp at about US$ 1.2 billion.

The stock of Hero MotoCorp ended the day trading higher by 2.2%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Telecom Stocks Bleed". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.